Eight biotechnology companies leading the charge in Poland By Jules Adam Add Labiotech as your Google Preferred Source 7 minutesmins July 13, 2026 7 minutesmins Share WhatsApp Twitter Linkedin Email Photo credits: Lasma Artmane Add Labiotech as your Google Preferred Source Newsletter Signup - Under Article / In Page"*" indicates required fieldsCommentsThis field is for validation purposes and should be left unchanged.Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*Company name*Job title*Business email* Over the last decade, Poland has seen the rise of its biotech industry. While the country’s pharmaceutical industry has traditionally focused on developing generics, many of these companies have started moving towards developing biologics. Meanwhile, biotech startups in Poland are working on developing new technologies, with a strong focus on treatments for cancer and autoimmune disease. As the country sees success stories in its biotech sector, more and more academics and entrepreneurs have been encouraged to start a business in Poland’s biotech industry. Here, we have selected eight companies at the forefront of Poland’s promising biotech industry. Table of contentsCaptor Therapeutics Headquarters: Wrocław, Poland Technology: Targeted protein degradation Lead asset: CT-01 With offices in Wrocław and Basel, Captor Therapeutics uses a proprietary targeted protein degradation (TPD) platform to discover and develop drugs that selectively eliminate disease-causing proteins. This approach allows the company to pursue therapeutic targets that have traditionally been considered difficult or impossible to drug. Its pipeline spans oncology, autoimmune and neurodegenerative diseases, combining proprietary drug candidates with partnered discovery programs. In 2025, Captor advanced its lead candidate, CT-01, into clinical testing for hepatocellular carcinoma, marking the company’s transition to a clinical-stage biotech. Alongside CT-01, Captor is advancing CT-03, an MCL-1 degrader for hematological cancers, which received support from the European Innovation Council Accelerator to help prepare the program for clinical development. Captor Therapeutics has been listed on the Warsaw Stock Exchange since 2021. Beyond its internal pipeline, the company continues to expand its targeted protein degradation platform through collaborations, including a partnership with Japan’s Ono Pharmaceutical to develop therapies for neurodegenerative diseases. Celon Pharma Headquarters: Kiełpin, Poland Technology: Small molecules, biologics and mRNA platforms Lead assets: CPL’36 for schizophrenia and Parkinson’s disease; Falkieri for treatment-resistant depression Celon Pharma combines a commercial portfolio of generic medicines with an expanding pipeline in neuroscience, oncology, metabolic diseases, and RNA therapeutics. The company reinvests revenues from its commercial business into the development of novel drug candidates. Its most advanced clinical programs include CPL’36 (alofropodect), which is being developed for schizophrenia and Parkinson’s disease levodopa-induced dyskinesia and has advanced following positive phase 2 results, as well as Falkieri, an intranasal esketamine treatment for treatment-resistant depression that is ready to enter phase 3 development. Beyond its clinical pipeline, Celon is also investing in bispecific antibody-drug conjugates and an mRNA platform designed for subcutaneous delivery. In 2026, four of the company’s projects were selected for funding by Poland’s Medical Research Agency. Ingenix Headquarters: Warsaw, Poland Technology: AI-powered drug discovery Lead platform: Biological Reasoning Engine Founded in 2023, Ingenix is an AI-driven biotechnology company developing a Biological Reasoning Engine designed to support drug discovery and development. The company’s proprietary Modality Fusion architecture integrates data across biological scales, including omics, clinical data, and scientific literature, to generate mechanistic hypotheses and support translational research. The platform is designed to help pharmaceutical and biotechnology companies identify drug targets, biomarkers, and clinical development strategies. In 2026, Ingenix raised a €13 million ($14.8 million) seed-extension round led by Sofinnova Partners. The funding will support the expansion of its Biological Reasoning Engine and collaborations with pharmaceutical and biotech companies through its Qualified Access Program. Molecure Headquarters: Warsaw, Poland Technology: First-in-class small-molecule therapeutics Lead asset: OATD-01 Formerly OncoArendi Therapeutics, Molecure develops first-in-class small molecules targeting previously unexplored proteins for the treatment of inflammatory, fibrotic, and oncological diseases. Listed on the Warsaw Stock Exchange, the company has built a clinical-stage pipeline led by OATD-01, a CHIT1 inhibitor currently in phase 2 trials for pulmonary sarcoidosis, alongside OATD-02, a dual ARG1/ARG2 inhibitor in phase 1 for solid tumors. In 2026, Molecure streamlined its strategy by discontinuing its RNA platform and concentrating resources on its two clinical programs. At the same time, the company launched a government-backed artificial intelligence (AI) initiative aimed at accelerating the discovery and development of new small-molecule drugs. PolTREG Headquarters: Gdańsk, Poland Technology: Regulatory T-cell (Treg) therapies Lead asset: PTG-007 PolTREG develops regulatory T-cell (Treg) therapies designed to restore immune tolerance in autoimmune diseases. Its lead program, PTG-007, is being developed for type 1 diabetes, while the company is also advancing programs for multiple sclerosis and expanding into next-generation CAR-Treg therapies for autoimmune and neuroinflammatory disorders. In 2026, the European Medicines Agency confirmed the therapy’s eligibility for submission of a centralized marketing authorization application for type 1 diabetes. Suggested Articles Navigating German biotech: 14 key players to know Swiss biotech going strong in 2025: 19 companies to put on your radar Biotech in Vienna: a budding life science hub The company also operates its own GMP manufacturing facility to support the production of advanced cell therapies. In 2025, PolTREG further expanded its platform through a partnership with Antion Biosciences to develop allogeneic CAR-Treg therapies. Pure Biologics Headquarters: Wrocław, Poland Technology: Antibody therapeutics Lead asset: PBA-0405 (PB004) Pure Biologics develops antibody-based therapies for cancer, with a particular focus on immuno-oncology. The company’s pipeline is built around proprietary antibody technologies designed to stimulate anti-tumor immune responses, alongside a smaller portfolio of aptamer-based projects. Its two lead programs, PBA-0405 (PB004) and PBA-0111 (PB003G), have both advanced into early clinical testing in the United States. In late 2024, Pure Biologics signed a licensing agreement with U.S.-based Promittens Corporation covering both PB004 and PB003G. The deal included an upfront payment of up to $9 million, potential milestone payments of up to $299 million, and royalties. While antibodies remain its primary focus, Pure Biologics also continues to develop aptamer-based technologies through its subsidiary Doto Medical. Ryvu Therapeutics Headquarters: Kraków, Poland Technology: Precision oncology small molecules Lead asset: RVU120 (romaciclib) Ryvu Therapeutics is developing precision oncology therapies targeting specific molecular drivers of cancer. Formed in 2019 following the split of Selvita’s therapeutic and contract research businesses, the company has built a pipeline of small-molecule drug candidates in oncology. Its lead program, RVU120 (romaciclib), is a selective CDK8/CDK19 inhibitor in phase 2 clinical development for relapsed or refractory acute myeloid leukemia (AML), high-risk myelodysplastic syndromes and myelofibrosis. Beyond RVU120, Ryvu’s pipeline includes dapolsertib, a dual PIM/FLT3 inhibitor partnered with Menarini, and RVU305, a brain-penetrant PRMT5 inhibitor for MTAP-deleted cancers. In 2025, the company streamlined its pipeline and reduced its workforce to focus resources on its most advanced programs and extend its financial runway. More recently, Ryvu reported positive feedback from the U.S. Food and Drug Administration (FDA) supporting the continued development of RVU120 in combination with venetoclax for relapsed or refractory AML. VAXICAN Headquarters: Gdańsk, Poland Technology: Therapeutic cancer vaccines (eVLP platform) Lead platform: Enveloped virus-like particle (eVLP) technology Founded as a spinout from the University of Gdańsk, VAXICAN is developing therapeutic cancer vaccines based on its proprietary enveloped virus-like particle (eVLP) platform. Its candidates are designed to stimulate the immune system to recognize and attack tumors. The company’s lead preclinical programs target HER2-positive breast cancer and GD2-expressing neuroblastoma, while its platform is intended to be adaptable to multiple cancer types. In late 2025, VAXICAN raised PLN 10.5 million ($2.8 million) in a seed round led by DeepTech Capital Consortium to advance its first two therapeutic cancer vaccine candidates toward clinical readiness. The company is also working to scale the manufacturing of its HER2-targeting vaccine. Poland’s biotech ecosystem continues to mature Poland’s biotechnology sector may still be smaller than Europe’s established hubs, but it is becoming increasingly diverse. Alongside a growing number of clinical-stage companies, the country is producing university spinouts, AI-driven drug discovery platforms, and next-generation cell and RNA therapy developers. According to the Polish Investment and Trade Agency’s 2025 Life Science Sector in Poland report, the country’s strengths lie in its scientific workforce, expanding collaboration between academia and industry, and increasing interest from international investors. As more Polish biotechs move innovative therapies into the clinic and attract global partners, the country’s life sciences sector is strengthening its position within the European landscape. This article was originally published in September 2019 by Clara Rodriguez Fernandez and has since been updated by Jules Adam in July 2026.This article is reserved for subscribers Subscribe for free to continue reading.Enter your details to log in or subscribe. Email Company name Job title Continue Readingor Continue with Microsoft Continue with LinkedIn By continuing, I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy. Organoids in cancer research: Paving the way for faster drug development across cancer indications This webinar explores how patient-derived organoids (PDOs) are redefining oncology research. Discover how advanced, well-characterized models empower researchers to streamline candidate selection, accelerate orphan drug programs, and deliver transformative therapies to patients faster than ever. Watch now Explore other topics: Autoimmune diseasebiotech startupCancerDrug deliveryPoland ADVERTISEMENT